시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 신경성 방광근 과활동 시장 보고서(2025년)
Neurogenic Detrusor Overactivity Global Market Report 2025
상품코드 : 1769672
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,448,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,320,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,193,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

신경성 방광근 과활동 시장 규모는 향후 수년간 강력한 성장이 예상될 예정입니다. 신경 장애는 뇌, 척수 또는 신경에 영향을 미치는 의학적 상태로, 운동, 감각, 인지 또는 기타 신체 기능에 문제를 일으킵니다. 인구 고령화로 인해 뇌 퇴화 위험이 증가함에 따라 이러한 질환의 유병률도 높아지고 있습니다. NDO는 척수 손상, 다발성 경화증, 파킨슨병 등 신경계 질환과 연관된 방광 기능 장애의 한 형태입니다. 이러한 질환은 뇌와 방광 사이의 정상적인 신경 신호 전달을 방해해 방광의 비자발적 수축을 유발합니다.

신경성 방광근 과활동 치료에 종사하는 주요 기업들은 저렴한 비용으로 효과적인 방광 조절 솔루션을 제공하기 위해 베타-3 아드레날린 수용체 작용제 등 첨단 제네릭 치료제 개발을 강조하고 있습니다. 미라베그론과 같은 이러한 의약품은 방광의 배뇨근을 이완시켜 방광 용량을 늘리고 절박감 및 요실금과 같은 증상을 완화합니다. 예를 들어, 2024년 4월, 인도 제약 회사인 Lupin Ltd.는 미국 식품의약국(USFDA)으로부터 Myrbetriq의 제네릭 의약품인 Mirabegron을 미국에서 출시할 수 있는 승인을 받았습니다. 1일 1회 경구 투여하는 Mirabegron은 소아 환자의 과민성 방광(OAB) 및 신경성 방광근 과활동을 관리하기 위한 편리하고 효율적인 옵션입니다. 이 승인은 루핀이 핵심 치료 분야에서 고품질 및 저렴한 제네릭 의약품을 제공하기 위한 노력을 강조합니다.

2024년 11월, 미국 의료기기 기업 보스턴 사이언티픽 코퍼레이션(Boston Scientific Corporation)은 신경 조절 및 비뇨기과 분야 포트폴리오를 강화하기 위해 액소닉스 인크(Axonics, Inc.)를 인수했습니다. 이 인수는 Axonics의 혁신적인 천골 신경 조절 기술을 통합하여 과민성 방광 및 기타 비뇨기 및 장 기능 장애 치료에 대한 Boston Scientific의 역량을 강화하기 위한 것입니다. Axonics의 솔루션을 통합함으로써 Boston Scientific은 골반 건강 상태에 대해 보다 포괄적인 치료 옵션을 제공할 수 있게 될 것입니다. Axonics, Inc.는 방광 조절을 개선하기 위해 설계된 천골 신경 조절 시스템을 전문으로 하는 미국에 본사를 둔 의료 기술 회사입니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 19 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별, 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

HBR
영문 목차

영문목차

Neurogenic detrusor overactivity (NDO) is a bladder dysfunction that results from neurological conditions interfering with normal nerve signals between the brain, spinal cord, and the bladder's detrusor muscle. This disruption causes increased or involuntary contractions of the detrusor muscle, leading to symptoms such as urinary urgency, frequent urination, urge incontinence, and occasionally incomplete bladder emptying.

The primary treatment options for neurogenic detrusor overactivity (NDO) include non-surgical treatments, surgical interventions, and follow-up care. Non-surgical treatments involve medical management or therapies that address the condition without requiring invasive surgical procedures. These treatments are utilized across different patient groups, including both adults and children, and are delivered in various settings such as hospitals, urology clinics, rehabilitation centers, private practices, and long-term care facilities.

The neurogenic detrusor overactivity market research report is one of a series of new reports from The Business Research Company that provides neurogenic detrusor overactivity market statistics, including the neurogenic detrusor overactivity industry global market size, regional shares, competitors with the neurogenic detrusor overactivity market share, detailed neurogenic detrusor overactivity market segments, market trends, and opportunities, and any further data you may need to thrive in the neurogenic detrusor overactivity industry. These neurogenic detrusor overactivity market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurogenic detrusor overactivity market size has grown strongly in recent years. It will grow from $1.69 billion in 2024 to $1.82 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The historic growth is attributed to a rise in neurological disorders, increased awareness among healthcare providers, broader adoption of pharmaceutical treatments, development of hospital and clinic facilities, and higher diagnosis rates.

The neurogenic detrusor overactivity market size is expected to see strong growth in the next few years. It will grow to $2.45 billion in 2029 at a compound annual growth rate (CAGR) of 7.7%. Growth drivers for the forecast period include the aging population, rising cases of spinal cord injuries, increased healthcare spending, advancements in minimally invasive therapies, and enhanced patient awareness and education. Key trends during this period include technological progress in stem cell therapies, innovation in drug delivery systems, improvements in neuromodulation devices, advances in personalized medicine research, and the development of less invasive treatment procedures.

The rising incidence of neurological disorders is expected to drive the growth of the neurogenic detrusor overactivity (NDO) market in the coming years. Neurological disorders are medical conditions that affect the brain, spinal cord, or nerves, resulting in issues with movement, sensation, cognition, or other bodily functions. As people live longer, the likelihood of age-related brain degeneration increases, contributing to the growing prevalence of these conditions. NDO is a form of bladder dysfunction often linked to neurological disorders such as spinal cord injury, multiple sclerosis, and Parkinson's disease. These conditions interfere with normal nerve communication between the brain and bladder, leading to involuntary bladder contractions. For example, in April 2024, a study published by the American Academy of Neurology (AAN) indicated that there will be an estimated 4.9 billion cases of brain disorders globally by 2050, marking a 22% increase from around 4 billion cases in 2021. Consequently, the increasing number of neurological disorders is contributing to the expansion of the NDO market.

Major companies involved in the treatment of neurogenic detrusor overactivity are emphasizing the development of advanced generic therapies, such as beta-3 adrenergic receptor agonists, to provide effective bladder control solutions at lower costs. These drugs, such as mirabegron, help relax the detrusor muscle in the bladder, thereby enhancing bladder capacity and reducing symptoms like urgency and incontinence. For instance, in April 2024, Lupin Ltd., an Indian pharmaceutical company, received approval from the U.S. Food and Drug Administration (USFDA) to launch Mirabegron, a generic version of Myrbetriq, in the United States. As a once-daily oral treatment, Mirabegron provides a convenient and efficient option for managing overactive bladder (OAB) and neurogenic detrusor overactivity in pediatric patients. This approval underscores Lupin's commitment to offering high-quality and affordable generic medications in key therapeutic areas.

In November 2024, Boston Scientific Corporation, a U.S.-based medical device company, acquired Axonics, Inc. to strengthen its portfolio in neuromodulation and urology. This acquisition aims to enhance Boston Scientific's capabilities in treating overactive bladder and other urinary and bowel dysfunctions by incorporating Axonics' innovative sacral neuromodulation technologies. The integration of Axonics' solutions will allow Boston Scientific to offer more comprehensive care options for pelvic health conditions. Axonics, Inc. is a U.S.-based medical technology firm that specializes in sacral neuromodulation systems designed to improve bladder control.

Major players in the neurogenic detrusor overactivity market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Sanofi S. A., Medtronic plc, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Intas Pharmaceuticals Ltd., Macleods Pharmaceuticals Ltd., Sun Pharmaceutical Industries, Apotex Inc., Viatris Inc., Sumitomo Pharma America Inc., Galderma, Ipsen, Coloplast A/S, Aurobindo Pharma Limited, Hisamitsu Pharmaceutical Co. Inc., Kaken Pharmaceutical Co. Ltd., and Hugel Inc.

North America was the largest region in the neurogenic detrusor overactivity market in 2024. The regions covered in neurogenic detrusor overactivity report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurogenic detrusor overactivity market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurogenic detrusor overactivity market includes revenues earned by entities by providing services such as medication management, behavioral and lifestyle interventions, physiotherapy, absorbent products and skin care, and catheterization. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurogenic Detrusor Overactivity Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurogenic detrusor overactivity market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for neurogenic detrusor overactivity ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurogenic detrusor overactivity market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Neurogenic Detrusor Overactivity Market Characteristics

3. Neurogenic Detrusor Overactivity Market Trends And Strategies

4. Neurogenic Detrusor Overactivity Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Neurogenic Detrusor Overactivity Growth Analysis And Strategic Analysis Framework

6. Neurogenic Detrusor Overactivity Market Segmentation

7. Neurogenic Detrusor Overactivity Market Regional And Country Analysis

8. Asia-Pacific Neurogenic Detrusor Overactivity Market

9. China Neurogenic Detrusor Overactivity Market

10. India Neurogenic Detrusor Overactivity Market

11. Japan Neurogenic Detrusor Overactivity Market

12. Australia Neurogenic Detrusor Overactivity Market

13. Indonesia Neurogenic Detrusor Overactivity Market

14. South Korea Neurogenic Detrusor Overactivity Market

15. Western Europe Neurogenic Detrusor Overactivity Market

16. UK Neurogenic Detrusor Overactivity Market

17. Germany Neurogenic Detrusor Overactivity Market

18. France Neurogenic Detrusor Overactivity Market

19. Italy Neurogenic Detrusor Overactivity Market

20. Spain Neurogenic Detrusor Overactivity Market

21. Eastern Europe Neurogenic Detrusor Overactivity Market

22. Russia Neurogenic Detrusor Overactivity Market

23. North America Neurogenic Detrusor Overactivity Market

24. USA Neurogenic Detrusor Overactivity Market

25. Canada Neurogenic Detrusor Overactivity Market

26. South America Neurogenic Detrusor Overactivity Market

27. Brazil Neurogenic Detrusor Overactivity Market

28. Middle East Neurogenic Detrusor Overactivity Market

29. Africa Neurogenic Detrusor Overactivity Market

30. Neurogenic Detrusor Overactivity Market Competitive Landscape And Company Profiles

31. Neurogenic Detrusor Overactivity Market Other Major And Innovative Companies

32. Global Neurogenic Detrusor Overactivity Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurogenic Detrusor Overactivity Market

34. Recent Developments In The Neurogenic Detrusor Overactivity Market

35. Neurogenic Detrusor Overactivity Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기